In the TCGA-HCC cohort, patients with high HtrA2 expression showed shorter overall survival (OS, HR = 1.73, 95% CI: 1.21–2.46, P=0.002, Figure 2(a)), disease-specific survival (DSS, HR = 2.14, 95% CI: 1.35–3.39, P=0.001, Figure 2(b)), and progression-free interval (PFI, HR = 1.64, 95% CI: 1.22–2.21, P=0.001, Figure 2(c)) relative to the patients with low HtrA2 expression. Here, HTRA2 is linked to hepatocellular carcinoma.